Oblimersen, an 18-base antisense oligonucleotide that mediates cleavage of Bcl-2 mRNA, when supplemented to dacarbazine significantly improved multiple clinical outcomes in patients with advanced melanoma and increased overall survival in patients with normal baseline serum LDH.[ 86 ] In a meta-analysis, progression-free survival, response and durable response rates showed a highly significant difference favoring dacarbazine oblimersen while a nearly significant trend was noted in the overall survival.
← all excerpts
Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.
1
—
—